|
|
8229 Boone Boulevard, Suite 802
Vienna, VA 22182 USA
phone:(703) 506-9460
fax:(703) 506-9471
|
|
| Symbol |
CVM |
| Exchange |
AMEX |
| Founded |
1983 |
| Employees |
32 |
|
|
| www.cel-sci.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Medicines for the treatment of cancer and infectious diseases. |
|
| Management |
| Maximilian de Clara, Director and President; Geert R. Kersten, Director and Chief Executive Officer; Patricia B. Prichep, Senior Vice President of Operations Secretary; Eyal Talor, Ph.D., Senior Vice President of Research and Manufacturing; Maximilian de Clara, Chairman and President, CEL-SCI Corporation |
| |
|
|
|
|
|
|
|
| Keywords |
| multikine, immunotherapy, alzheimer, peptide epitope, peptide antigen |
|
|
|
| Description |
|
Its story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its cancer therapy, CEL-SCI is finally at the end game! their lead cancer product, Multikine, has performed well in Phase II trials, and is now approved for a global Phase III trial.The story began at the Max Plank Institute in Germany in the late 1970s, with groundbreaking science and research supporting the theory that the immune system could fight cancer. Maximilian de Clara, the Company�s founder, believed strongly that the immune system played an important role in fighting this disease, but he lacked the technology to turn his idea into a product.. |
|
| Products / Services |
The Company's first and main product, Multikine, manufactured using its proprietary cell culture technologies, is a combination or cocktail of natural human interleukin-2 (IL-2) and certain lymphokines and cytokines. CEL-SCI's patented T-cell Modulation Process uses heteroconjugates to direct the body to choose a specific immune response to more effectively fight bacterial, viral and parasitic infections and cancer when it cannot do so on its own.
|
|
|
| Competitors / Substitutes / Alternatives |
Antigenics Inc. Chiron Corporation Progenics Pharmaceuticals, Inc. VaxGen, Inc.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
